Display options
Cite
Ferrucci PF, Gandini S, Cocorocchio E, et al. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 2017;8(45):79809-79815doi: 10.18632/oncotarget.19748.
Ferrucci, P. F., Gandini, S., Cocorocchio, E., Pala, L., Baldini, F., Mosconi, M., Antonini Cappellini, G. C., Albertazzi, E., & Martinoli, C. (2017). Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget, 8(45), 79809-79815. https://doi.org/10.18632/oncotarget.19748
Ferrucci, Pier Francesco, et al. "Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma." Oncotarget vol. 8,45 (2017): 79809-79815. doi: https://doi.org/10.18632/oncotarget.19748
Ferrucci PF, Gandini S, Cocorocchio E, Pala L, Baldini F, Mosconi M, Antonini Cappellini GC, Albertazzi E, Martinoli C. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 2017 Aug 01;8(45):79809-79815. doi: 10.18632/oncotarget.19748. eCollection 2017 Oct 03. PMID: 29108362; PMCID: PMC5668095.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 01;8(45):79809-79815. doi: 10.18632/oncotarget.19748. eCollection 2017 Oct 03.

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.

Oncotarget

Pier Francesco Ferrucci, Sara Gandini, Emilia Cocorocchio, Laura Pala, Federica Baldini, Massimo Mosconi, Gian Carlo Antonini Cappellini, Elena Albertazzi, Chiara Martinoli

Affiliations

  1. Medical Oncology of Melanoma Unit, Division of Medical Oncology of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy.
  2. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
  3. Division of Surgery of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy.
  4. IV Oncology Division, Istituto Dermopatico dell'Immacolata IRCCS, Rome, Italy.

PMID: 29108362 PMCID: PMC5668095 DOI: 10.18632/oncotarget.19748

Abstract

As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model based on baseline serum lactate dehydrogenase (LDH), peripheral blood relative lymphocyte counts (RLC) and eosinophil counts (REC) and pattern of distant metastasis, has been recently proposed for pembrolizumab-treated patients. Here, we applied this model to advanced melanoma patients receiving chemotherapy (

Keywords: biomarker; eosinophil; ipilimumab; melanoma; predictive

Conflict of interest statement

CONFLICTS OF INTEREST Pier Francesco Ferrucci participated to advisory boards and received travel grants from Bristol-Myers Squibb, Roche, MSD and Novartis. Emilia Cocorocchio served as a consultant f

References

  1. Curr Oncol Rep. 2016 Apr;18(4):21 - PubMed
  2. J Immunother Cancer. 2017 May 16;5:44 - PubMed
  3. Oncologist. 2011;16(1):5-24 - PubMed
  4. Lancet. 2014 Sep 20;384(9948):1109-17 - PubMed
  5. Clin Cancer Res. 2016 Jun 15;22(12):2908-18 - PubMed
  6. Br J Dermatol. 2016 Jan;174(1):146-51 - PubMed
  7. Eur J Cancer. 2016 Jan;53:125-34 - PubMed
  8. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  9. J Clin Oncol. 2015 Nov 20;33(33):3968-71 - PubMed
  10. Br J Cancer. 2015 Jun 9;112(12 ):1904-10 - PubMed
  11. N Engl J Med. 2011 Jun 30;364(26):2517-26 - PubMed
  12. N Engl J Med. 2015 Jun 25;372(26):2521-32 - PubMed
  13. Clin Cancer Res. 2015 Dec 15;21(24):5453-9 - PubMed
  14. Lancet Oncol. 2015 Apr;16(4):375-84 - PubMed
  15. J Clin Oncol. 2009 Dec 20;27(36):6199-206 - PubMed
  16. Clin Cancer Res. 2016 Oct 1;22(19):4848-4858 - PubMed
  17. Ann Oncol. 2016 Apr;27(4):732-8 - PubMed
  18. Clin Cancer Res. 2016 Nov 15;22(22):5487-5496 - PubMed
  19. Science. 2016 May 6;352(6286):658-60 - PubMed
  20. Ann Oncol. 2013 Jun;24(6):1697-703 - PubMed

Publication Types